Table 3. Logistic Multivariable Analysis for High Neutrophil-Lymphocyte Ratio.
| Characteristic | aOR (95% CI) | P value |
|---|---|---|
| Gender | ||
| Male | 1 [Reference] | NA |
| Female | 2.18 (0.95-4.91) | .06 |
| Smoker | ||
| Never | 1 [Reference] | NA |
| Current | 1.50 (0.50-4.64) | .47 |
| Former | 1.18 (0.46-3.26) | .73 |
| Age, y | ||
| <65 | 1 [Reference] | NA |
| ≥65 | 0.46 (0.20-1.03) | .07 |
| Year of radiation | ||
| 2014 or earlier | 1 [Reference] | NA |
| 2015 or later | 0.98 (0.48-1.99) | .96 |
| KPS | ||
| <90 | 1 [Reference] | NA |
| 90-100 | 0.29 (0.14-0.59) | <.001 |
| Race | ||
| White | 1 [Reference] | NA |
| Othera | 0.63 (0.20-1.68) | .38 |
| Comorbidity | ||
| 0 | 1 [Reference] | NA |
| 1 | 0.66 (0.23-1.97) | .45 |
| 2 | 1.38 (0.47-4.15) | .56 |
| 3 | 0.18 (0.04-0.70) | .02 |
| >3 | 0.37 (0.11-1.19) | .10 |
| Site | ||
| Oropharynx | 1 [Reference] | NA |
| Larynx | 1.30 (0.46-3.61) | .62 |
| Oral cavity | 1.88 (0.20-11.95) | .54 |
| Other | 0.81 (0.27-2.19) | .68 |
| T staging | ||
| 1-2 | 1 [Reference] | NA |
| 3-4 | 4.07 (1.92-9.16) | <.001 |
| N staging | ||
| 0 | 1 [Reference] | NA |
| 1 | 2.16 (0.55-8.10) | .26 |
| 2 | 2.97 (1.04-9.17) | .049 |
| 3 | 11.21 (2.84-46.97) | <.001 |
| HPV | ||
| Negative | 1 [Reference] | NA |
| Positive | 0.45 (0.16-1.19) | .11 |
| Chemotherapy | ||
| Cisplatin | 1 [Reference] | NA |
| Other | 4.24 (1.74-10.36) | .001 |
Abbreviations: aOR, adjusted odds ratio; HPV, human papillomavirus; KPS, Karnofsky performance status; NA, not applicable.
a
The other category for race and ethnicity included African American, American Indian or Alaska Native, Asian, Hispanic, and those who were unknown or declined to answer.